FibroGen Q3 revenue up 155% to $40.1M; roxadustat China sales up 31%

KYNTRA BIO, INC.

2023-Q3 EPS reported -$2.35 revenue$120,614,000

Net loss of $63.6M ($0.65 loss per share) vs $91.7M ($0.98) YoY; restructuring charge of $12.6M.
Roxadustat net product revenue in China reached $29.4M, up 69% YoY; total China sales $77.1M (up 31%), driven by 37% volume growth.
Annualized cost reduction of $120M implemented; cash of $283.0M expected to fund operations into 2026.
Pamrevlumab LAPIS Phase 3 topline data expected Q1 2024; PanCAN Phase 2/3 data in 1H 2024.
sNDA for roxadustat in chemotherapy-induced anemia accepted in China; approval decision mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

KYNTRA BIO, INC. reported third quarter 2023 results: revenue Total revenue for the third quarter of 2023 was $40.1 million, net income Net loss for the third quarter of 2023 was $63.6 million, or $0.65 net loss per basic and diluted share, EPS $0.65 net loss per basic and diluted share.

Period: third quarter 2023
Revenue: Total revenue for the third quarter of 2023 was $40.1 million
Net income: Net loss for the third quarter of 2023 was $63.6 million, or $0.65 net loss per basic and diluted share
EPS: $0.65 net loss per basic and diluted share
Result: reported results

Exact text from the filing

FibroGen Reports Third Quarter 2023 Financial Results

View on SEC.gov

Browse all earnings releases →

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-059381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.